Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis

BACKGROUND: Patients receiving in-centre hemodialysis are at high risk of exposure to SARS-CoV-2 and death if infected. One dose of the BNT162b2 SARS-CoV-2 vaccine is efficacious in the general population, but responses in patients receiving hemodialysis are uncertain. METHODS: We obtained serial pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Goupil, Rémi, Benlarbi, Mehdi, Beaubien-Souligny, William, Nadeau-Fredette, Annie-Claire, Chatterjee, Debashree, Goyette, Guillaume, Gunaratnam, Lakshman, Lamarche, Caroline, Tom, Alexander, Finzi, Andrés, Suri, Rita S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Joule Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177936/
https://www.ncbi.nlm.nih.gov/pubmed/33980499
http://dx.doi.org/10.1503/cmaj.210673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177936/
https://www.ncbi.nlm.nih.gov/pubmed/33980499
http://dx.doi.org/10.1503/cmaj.210673

Ejemplares similares